BB-Cl-Amidine

• Description:

  BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Protein Arginine Deiminase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/BB-Cl-Amidine.html

• Purity:

  98.19

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=C(C2=CC=CC=C2)C=C1)N[C@H](C3=NC4=CC=CC=C4N3)CCCNC(CCl)=N

• Molecular Formula:

  C26H26ClN5O

• Molecular Weight:

  459.97

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Knight JS, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis. 2015 Dec;74 (12) :2199-206.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Citation 01:

  Cell Physiol Biochem. 2024 Feb 19;58 (1) :63-82.|Int Immunopharmacol. 2024 Nov 5;143 (Pt 3) :113534.|J Antibiot (Tokyo) . 2025 Oct 9.|Acta Neuropathol Commun. 2025 Feb 18;13 (1) :33.|Adv Sci (Weinh) . 2025 Aug 20:e11873.|Mol Med. 2025 Feb 5;31 (1) :46.|Nat Cell Biol. 2021 Oct;23 (10) :1060-1072.|Nat Commun. 2024 Sep 3;15 (1) :7654.|Oncol Rep. 2023 Jul;50 (1) :146.|Res Sq. 2024 Jun 04.

• CAS Number:

  1802637-39-3